Latest / Decera Clinical Education Oncology Podcast
From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL
In this episode, Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discuss how recently presented data from ASH 2025 are shaping real-world treatment decisions for patients with relapsed/refractory chronic lymphocytic leukemia, including:
How covalent and noncovalent BTK inhibitors are currently used in the United States, Brazil, and Europe
Practical sequencing decisions after disease progression
Emerging BTK degradersas a promising option for heavily pretreated patients
Get access to all of our new podcasts by subscribing to the Decera Clinical Education…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.